HIV Clinical and Research Program
Our program is currently accepting new patients and is focused on long-term health care. Advanced human immunodeficiency virus (HIV) treatment in this country has allowed many infected people to live long, happy lives. Therefore, our goal is to begin HIV treatment in the early stages of the disease and try to prevent the additional challenges that affect the aging HIV population.
We provide health maintenance for those conditions that affect the general population, such as cancer screening and cardiovascular disease prevention, and provide special screenings for HIV-associated conditions.
Our approach to treatment is aggressive to suppress the virus and maintain immunologic function. And our involvement in HIV research studies allows us to stay on the forefront of disease management.
Our program participates in the following HIV research studies:
HIV Outpatient Study (HOPS): This study collects and analyzes data from thousands of HIV patients' specific treatment regimens, outcomes, side effects, survival rates and other information. The study is performed in cooperation with the Centers for Disease Control and Prevention (CDC).
Study to understand the natural history of HIV (SUN): This study is designed to identify complications of HIV infection and its treatment with the goal of improving these outcomes. The study is sponsored by the CDC.
Pfizer: An observational, post-marketing study to assess the safety of maraviroc, an antiretroviral drug that prevents viral entry into the T-cell.
Abbvie: Pharmaceutically-sponsored study in conjunction with the National Jewish Health labs to identify inflammatory biomarkers that are associated with disease progression, cardiovascular complications, osteoporosis, lipodystrophy, and other HIV-associated co-morbid conditions.
Participant in the AIDS Clinical Trials Group studies of the National Institutes of Health (NIH) through the University of Colorado and Denver Health Medical Center in Denver.
Gilead Sciences: Evaluation of a new "booster" of protease inhibitors in comparison to ritonavir in HIV infected individuals who have never been on antiretroviral treatment.
Gilead Sciences: Evaluation of a new formulation of tenofovir that was designed to minimize toxicity to the kidney. It is one of the medications in the “quad” pill that is a full antiretroviral regimen taken as one pill once a day.